Skip to main content

AITBiotech Licenses Multiple Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Singapore genomics service firm AITBiotech announced it has licensed molecular assays developed by research institutes under Singapore's Agency for Science Technology and Research (A*STAR).

The assays were licensed from Exploit Technologies, the marketing and commercialization arm of A*STAR.
The agreement covers dengue/chikungunya multiplex detection kits and a Mycobacterium tuberculosis detection kit. The kits are used with PCR systems.

The assays were developed by Masafumi Inoue and his colleagues at A*STAR's Experimental Therapeutics Centre, AITBiotech said in a statement.

The company also has acquired the license to an H1NI whole-genome mutation detection system, developed by Christopher Wong and his team at the Genome Institute of Sinagpore. The test had a call rate of 99 percent and accuracy of 99.99 percent in testing of samples from Singapore and Mexico, according to AITBiotech.

The acquired assays are being used by hospitals in Thailand, it said, and are being evaluated by other hospitals in Singapore, Hong Kong, Malaysia, and Indonesia.

Terms of the agreements were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.